中国·亚星-www.333.com|百家乐官方网

Current Location：Home Investor RelationsDisclosure

Announcements and Circulars

072025.03
DISCLOSEABLE TRANSACTIONS IN RELATION TO SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS

Show More
062025.03
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025

Show More
032025.03
VOLUNTARY ANNOUNCEMENT APPROVAL OF SUPPLEMENTAL APPLICATION FOR QX001S (SAILEXIN, USTEKINUMAB INJECTION) FOR USE IN PEDIATRIC PLAQUE PSORIASIS

Show More
242025.02
VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL TRIAL OF QX002N FOR ANKYLOSING SPONDYLITIS REACHES PRIMARY ENDPOINT

Show More
122025.02
VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF MARKETING AUTHORISATION APPLICATION AND SUPPLEMENTAL APPLICATION FOR QX001S (USTEKINUMAB INJECTION) FOR USE IN CROHN'S DISEASE

Show More
062025.02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025

Show More

8 9 10 11 12 13 ... 20